
Vania Giacomet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2822407/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ventricular septal defect and aortic hypoplasia in congenital cytomegalovirus infection: occasional finding or underdetected correlation?. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 6558-6560.	0.7	2
2	Children living with HIV in Europe: do migrants have worse treatment outcomes?. HIV Medicine, 2022, 23, 186-196.	1.0	2
3	Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children. BMC Infectious Diseases, 2022, 22, 55.	1.3	2
4	Sofosbuvirâ€velpatasvirâ€voxilaprevir in adolescents 12 to 17 years old with HCV infection. Hepatology, 2022, 76, 445-455.	3.6	7
5	Congenital CMV, Lights and Shadows on Its Management: The Experience of a Reference Center in Northern Italy. Children, 2022, 9, 655.	0.6	5
6	Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018. Frontiers in Pediatrics, 2021, 9, 665764.	0.9	6
7	Dried Blood Spot as an Alternative to Plasma/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized to Facilitate COVID-19 Surveillance Among Schoolchildren. Pediatric Infectious Disease Journal, 2021, 40, e46-e47.	1.1	20
8	Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 95-100.	0.9	11
9	261â€Infant hematemesis: a challenging diagnosis, postnatal CMV infection or non IgE-mediated cow's milk protein allergy? A two case report comparison. , 2021, , .		0
10	Immunological Characterization of HIV and SARS-CoV-2 Coinfected Young Individuals. Cells, 2021, 10, 3187.	1.8	8
11	Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study. Infection, 2020, 48, 249-258.	2.3	11
12	Defining the clinical phenotype of COVIDâ€19 in children. Pediatric Allergy and Immunology, 2020, 31, 82-84.	1.1	4
13	Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreignâ€born Children With Chronic Hepatitis B. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 381-387.	0.9	4
14	Gastrointestinal Symptoms in Severe COVID-19 Children. Pediatric Infectious Disease Journal, 2020, 39, e317-e320.	1.1	45
15	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	3.1	273
16	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. Microorganisms, 2020, 8, 864.	1.6	7
17	Acute myocardial injury: a novel clinical pattern in children with COVID-19. The Lancet Child and Adolescent Health, 2020, 4, e26-e27.	2.7	34
18	Acute Inflammation and Elevated Cardiac Markers in a Two-Month-Old Infant with Severe Acute Respiratory Syndrome Coronavirus 2 Infection Presenting with Cardiac Symptoms. Pediatric Infectious Disease Journal, 2020, 39, e149-e151.	1.1	18

#	Article	IF	CITATIONS
19	Lyme borreliosis incidence in Lombardy, Italy (2000–2015): Spatiotemporal analysis and environmental risk factors. Ticks and Tick-borne Diseases, 2019, 10, 101257.	1.1	17
20	Vaginal delivery in women with HIV in Italy: results of 5Âyears of implementation of the national SIGO-HIV protocol. Infection, 2019, 47, 981-990.	2.3	1
21	Treatment and monitoring of children with chronic hepatitis C in the Preâ€DAA era: A European survey of 38 paediatric specialists. Journal of Viral Hepatitis, 2019, 26, 961-968.	1.0	15
22	Missed opportunities to prevent motherâ€ŧo hild transmission of HIV in Italy. HIV Medicine, 2019, 20, 330-336.	1.0	7
23	An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents. Expert Opinion on Pharmacotherapy, 2019, 20, 269-276.	0.9	3
24	Effects and safety of delayed versus early umbilical cord clamping in newborns of HIV-infected mothers. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 646-649.	0.7	9
25	Paediatric <scp>E</scp> uropean <scp>N</scp> etwork for <scp>T</scp> reatment of <scp>AIDS</scp> (<scp>PENTA</scp>) guidelines for treatment of paediatric <scp>HIV</scp> â€I infection 2015: optimizing health in preparation for adult life. HIV Medicine, 2018, 19, e1-e42.	1.0	78
26	Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 99-104.	0.9	3
27	Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1025-1030.	1.3	3
28	Strategies for Prevention of Mother-to-Child Transmission Adopted in the "Real-World―Setting: Data From the Italian Register for HIV-1 Infection in Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 54-61.	0.9	3
29	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65Âyears with HCV genotype 1 cirrhosis. Infection, 2018, 46, 607-615.	2.3	7
30	Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults. PLoS ONE, 2018, 13, e0192638.	1.1	8
31	Pregnancy-Related Changes of Antiretroviral Pharmacokinetics: An Argument for Therapeutic Drug Monitoring. Antiviral Therapy, 2017, 22, 361-363.	0.6	3
32	Amniocentesis and chorionic villus sampling in HIVâ€infected pregnant women: a multicentre case series. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1218-1223.	1.1	14
33	Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. HIV Medicine, 2017, 18, 440-443.	1.0	8
34	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. Respiratory Medicine, 2017, 132, 68-75.	1.3	7
35	Pregnant with HIV before age 25: data from a large national study in Italy, 2001–2016. Epidemiology and Infection, 2017, 145, 2360-2365.	1.0	2
36	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15

#	Article	IF	CITATIONS
37	A 10–year followâ^'up of bone mineral density in HIVâ^'infected youths receiving tenofovir disoproxil fumarate. International Journal of Antimicrobial Agents, 2017, 50, 365-370.	1.1	11
38	Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with <scp>HIV</scp> . HIV Medicine, 2017, 18, 133-134.	1.0	43
39	Management of newborns at risk of neonatal and perinatal tuberculosis. Asian Pacific Journal of Tropical Disease, 2017, 7, 569-571.	0.5	1
40	HCV–HIV coinfected pregnant women: data from a multicentre study in Italy. Infection, 2016, 44, 235-242.	2.3	19
41	Factors Affecting Outcome of Tuberculosis in Children in Italy: An Ecological Study. Advances in Experimental Medicine and Biology, 2016, 973, 71-79.	0.8	1
42	Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV. Clinical Microbiology and Infection, 2016, 22, 818-820.	2.8	2
43	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. Vaccine, 2016, 34, 5587-5594.	1.7	2
44	Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy. Prenatal Diagnosis, 2015, 35, 1374-1378.	1.1	3
45	HCV treatment in children and young adults with HIV/HCV co-infection in Europe. Journal of Virus Eradication, 2015, 1, 179-184.	0.3	9
46	Disseminated cerebral tuberculosis in an immunocompetent adolescent boy. Journal of Pediatric Infectious Diseases, 2015, 04, 425-428.	0.1	0
47	Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths. Endocrine, 2015, 49, 783-790.	1.1	13
48	Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. Aids, 2015, 29, 739-743.	1.0	9
49	Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A 132-Month Follow-Up Study. Clinical Drug Investigation, 2015, 35, 419-426.	1.1	12
50	HCV treatment in children and young adults with HIV/HCV co-infection in Europe. Journal of Virus Eradication, 2015, 1, 179-84.	0.3	5
51	Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. Indian Journal of Pediatrics, 2014, 81, 856-60.	0.3	1
52	Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus. HIV/AIDS - Research and Palliative Care, 2014, 6, 69.	0.4	5
53	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. HIV Clinical Trials, 2014, 15, 104-115.	2.0	11
54	Unexpected vertical transmission of HIV infection. European Journal of Pediatrics, 2014, 173, 121-123.	1.3	4

#	Article	IF	CITATIONS
55	Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine, 2014, 32, 5657-5661.	1.7	54
56	No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet, The, 2014, 384, 1320.	6.3	52
57	A case of laryngeal tuberculosis in a pediatric patient. Asian Pacific Journal of Tropical Disease, 2014, 4, S656-S658.	0.5	0
58	Areal Bone Mineral Density in Pediatric Patients with Chronic Hepatitis B or Chronic Hepatitis C. Calcified Tissue International, 2014, 95, 218-221.	1.5	5
59	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1377-1384.	1.3	13
60	Antiretroviral Therapy and Pregnancy: Effect on Cortical Bone Status of Human Immunodeficiency Virus–Infected Caucasian Women as Assessed by Quantitative Ultrasonography. Calcified Tissue International, 2013, 92, 394-398.	1.5	0
61	Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz. European Journal of Pediatrics, 2013, 172, 1089-1096.	1.3	10
62	Herpetic acute anterior uveitis complicated by retinal vasculitis in an immunocompetent child. Canadian Journal of Ophthalmology, 2013, 48, e171-e172.	0.4	3
63	Neurocysticercosis in a 14-year-old boy in Italy: An unexpected case. Asian Pacific Journal of Tropical Disease, 2013, 3, 324-326.	0.5	1
64	Resource utilization and direct costs of pediatric HIV in Italy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 1392-1398.	0.6	0
65	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. Clinical Infectious Diseases, 2013, 56, 1190-1193.	2.9	0
66	Birth defects in a national cohort of pregnant women with <scp>HIV</scp> infection in <scp>I</scp> taly, 2001–2011. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1466-1476.	1.1	34
67	Cholecalciferol Supplementation in HIV-Infected Youth with Vitamin D Insufficiency: Effects on Vitamin D Status and T-Cell Phenotype: A Randomized Controlled Trial. HIV Clinical Trials, 2013, 14, 51-60.	2.0	47
68	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. HIV Clinical Trials, 2013, 14, 110-119.	2.0	4
69	Tenofovir-induced Renal Tubular Dysfunction in Vertically HIV-infected Patients Associated With Polymorphisms in ABCC2, ABCC4 and ABCC10 Genes. Pediatric Infectious Disease Journal, 2013, 32, e403-e405.	1.1	15
70	Proteinuria in paediatric patients with human immunodeficiency virus infection. World Journal of Clinical Cases, 2013, 1, 13.	0.3	8
71	Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone, 2012, 50, 255-258.	1.4	11
72	Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. BMC Infectious Diseases, 2012, 12, 179.	1.3	5

#	Article	IF	CITATIONS
73	Antiretroviral use in Italian children with perinatal HIV infection over a 14â€year period. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, e287-95.	0.7	5
74	Fever and ascites underlying abdominal aspergillosis in a 3â€yearâ€old boy. Pediatrics International, 2012, 54, 311-312.	0.2	0
75	Splenomegaly and Variceal Bleeding in a Ten-year-old HIV-infected Girl With Noncirrhotic Portal Hypertension. Pediatric Infectious Disease Journal, 2012, 31, 1059-1060.	1.1	9
76	Morbidity rates in late preterms born to HIV-mothers. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 626-627.	0.7	1
77	Antiretroviral drugs in HIV-infected children. Pharmacological Research, 2011, 64, 1-3.	3.1	1
78	Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults. Clinical Drug Investigation, 2011, 31, 407-415.	1.1	24
79	First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infectious Diseases, The, 2011, 11, 273-283.	4.6	123
80	<i>In utero</i> exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antiviral Therapy, 2011, 16, 1259-1266.	0.6	58
81	Lipodystrophy, Insulin Resistance, and Adiponectin Concentration in HIV-Infected Children and Adolescents. Current HIV Research, 2011, 9, 321-326.	0.2	14
82	Flu and pneumococcal immunisations in HIV-infected children: methodological quality of current recommendations. BMJ Quality and Safety, 2011, 20, 432-439.	1.8	2
83	Risk of Perinatal HIV Infection in Infants Born in Italy to Immigrant Mothers. Clinical Infectious Diseases, 2011, 53, 310-313.	2.9	22
84	Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial. Vaccine Journal, 2011, 18, 1503-1509.	3.2	12
85	Tenofovir Disoproxil Fumarate and Bone Mineral Density: A 60-Month Longitudinal Study in a Cohort of H V -Infected Youths. Antiviral Therapy, 2010, 15, 1053-1058.	0.6	37
86	Italian consensus statement on paediatric HIV infection. Infection, 2010, 38, 301-319.	2.3	8
87	Mode of delivery in HIVâ€infected pregnant women and prevention of motherâ€ŧoâ€child transmission: changing practices in Western Europe. HIV Medicine, 2010, 11, 368-378.	1.0	73
88	Leprosy: A disease not to be forgotten in the era of globalization. Pediatrics International, 2010, 52, 849-850.	0.2	8
89	A dangerous freshwater contact. BMJ Case Reports, 2010, 2010, bcr0120102620-bcr0120102620.	0.2	1
90	Both HIV-Infection and Long-Term Antiretroviral Therapy are Associated with Increased Common Carotid Intima-Media Thickness in HIV-Infected Adolescents and Young Adults. Current HIV Research, 2010, 8, 411-417.	0.2	23

#	Article	IF	CITATIONS
91	Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone, 2010, 46, 1633-1638.	1.4	47
92	Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza. Vaccine, 2010, 28, 2700-2704.	1.7	13
93	Is the Interruption of Antiretroviral Treatment During Pregnancy an Additional Major Risk Factor for Motherâ€ŧo hild Transmission of HIV Type 1?. Clinical Infectious Diseases, 2009, 48, 1310-1317.	2.9	25
94	Differential effect of age, gender and puberty on bone formation rate assessed by measurement of bone-specific alkaline phosphatase in healthy Italian children and adolescents. Journal of Bone and Mineral Metabolism, 2009, 27, 721-726.	1.3	16
95	Long-Term Evaluation of Glucose Homeostasis in a Cohort of HAART-Treated HIV-Infected Children. Clinical Drug Investigation, 2009, 29, 101-109.	1.1	16
96	The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children. Expert Opinion on Pharmacotherapy, 2009, 10, 2773-2778.	0.9	13
97	Applicability of Quantitative Ultrasonography of the Radius and Tibia in HIV-Infected Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 588-592.	0.9	11
98	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. HIV Clinical Trials, 2008, 9, 287-297.	2.0	11
99	Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 289-296.	0.9	52
100	Successful Rescue Therapy with a Darunavir/Ritonavir and Etravirine Antiretroviral Regimen in a Child with Vertically Acquired Multidrug-Resistant HIV-1. Antiviral Therapy, 2008, 13, 839-843.	0.6	15
101	Time to Undetectable Viral Load after Highly Active Antiretroviral Therapy Initiation among HIV-Infected Pregnant Women. Clinical Infectious Diseases, 2007, 44, 1647-1656.	2.9	114
102	Immune activation and normal levels of endogenous antivirals are seen in healthy adolescents born of HIV-infected mothers. Aids, 2007, 21, 245-248.	1.0	16
103	Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. Aids, 2007, 21, 1129-1135.	1.0	32
104	Metabolic complications of HIV infection and its therapy in children. Future HIV Therapy, 2007, 1, 181-190.	0.5	3
105	Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine, 2007, 25, 6692-6698.	1.7	20
106	Adherence to antiretroviral therapy in children: A comparative evaluation of caregiver reports and physician judgement. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 764-766.	0.6	9
107	Renal Safety of Tenofovir in HIV-infected Children. Clinical Drug Investigation, 2007, 27, 573-581.	1.1	33
108	Modulation of innate and adaptive immunity by lactoferrin in human immunodeficiency virus (HIV)-infected, antiretroviral therapy-naÃ ⁻ ve children. International Journal of Antimicrobial Agents, 2007, 29, 353-355.	1.1	32

#	Article	IF	CITATIONS
109	Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antiviral Therapy, 2007, 12, 297-302.	0.6	18
110	Normalization of Fat Accrual in Lipoatrophic, HIV-Infected Children Switched from Stavudine to Tenofovir and from Protease Inhibitor to Efavirenz. Antiviral Therapy, 2007, 12, 297-302.	0.6	26
111	The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. Aids, 2006, 20, 1419-1427.	1.0	51
112	CD4 Cell Response to Antiretroviral Therapy in Children with Vertically Acquired HIV Infection: Is It Associated with Age at Initiation?. Journal of Infectious Diseases, 2006, 193, 954-962.	1.9	73
113	Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda. Annals of Tropical Paediatrics, 2006, 26, 169-179.	1.0	17
114	Increased CD36 Expression in Vertically Human Immunodeficiency Virus-Infected Children Unrelated to Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2005, 24, 576-577.	1.1	7
115	A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 448-450.	0.9	65
116	Analysis of Bone Mineral Content in Horizontally HIV-Infected Children NaÃ ⁻ ve to Antiretroviral Treatment. Calcified Tissue International, 2005, 76, 336-340.	1.5	31
117	Efficacy and tolerability of multiple drug therapy in HIV-infected children. Journal of Infection, 2005, 50, 404-411.	1.7	5
118	Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. Aids, 2005, 19, 1071-1079.	1.0	74
119	The management of HCV infected pregnant women and their children European paediatric HCV network. Journal of Hepatology, 2005, 43, 515-525.	1.8	81
120	Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antiviral Therapy, 2005, 10, 917-24.	0.6	20
121	Nucleoside Analogues Toxicities Related to Mitochondrial Dysfunction: Focus on HIV-Infected Children. Antiviral Therapy, 2005, 10, 53-64.	0.6	4
122	Improvement in Dyslipidaemia after Switching Stavudine to Tenofovir and Replacing Protease Inhibitors with Efavirenz in HIV-Infected Children. Antiviral Therapy, 2005, 10, 917-924.	0.6	43
123	Longitudinal Changes of Bone Mineral Density and Metabolism in Antiretroviral-Treated Human Immunodeficiency Virus-Infected Children. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 24-28.	1.8	99
124	Growth hormone in T-lymphocyte thymic and postthymic development: A study in HIV-infected children. Journal of Pediatrics, 2004, 145, 542-548.	0.9	32
125	Combined antiretroviral therapy reduces hyperimmunoglobulinemia in HIV-1 infected children. Aids, 2004, 18, 1423-1428.	1.0	11
126	Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. Aids, 2004, 18, 2009-2017.	1.0	86

#	Article	IF	CITATIONS
127	Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatric Infectious Disease Journal, 2003, 22, 56-62.	1.1	140
128	Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatrica, International Journal of Paediatrics, 2003, 92, 1398-1402.	0.7	30
129	Increased Thymic Output after Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus Type 1–Infected Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. Journal of Infectious Diseases, 2002, 186, 312-320.	1.9	73
130	Effects of Nutritional Rehabilitation on Intestinal Function and on CD4 Cell Number in Children With HIV. Journal of Pediatric Gastroenterology and Nutrition, 2002, 34, 366-371.	0.9	21
131	Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. Aids, 2002, 16, 839-849.	1.0	62
132	Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys?. Aids, 2002, 16, 97-104.	1.0	55
133	Impact of Human Immunodeficiency Virus Type 1 Subtypes on Virologic Response and Emergence of Drug Resistance among Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. Journal of Infectious Diseases, 2002, 186, 617-625.	1.9	104
134	Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. Aids, 2001, 15, 1527-1534.	1.0	55
135	Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. Aids, 2001, 15, 1074-1075.	1.0	46
136	HIV: mother to child transmission, current knowledge and on-going studies. International Journal of Gynecology and Obstetrics, 1998, 63, S161-S165.	1.0	9
137	Social care of children born to HIV-infected parents. Lancet, The, 1992, 339, 189-190.	6.3	10